Anti-Cullin 3/CUL-3 antibody [EPR3195]
- RabMAb
- Recombinant
- What is this?
4
(1 Review)
|
(12 Publications)
Rabbit Recombinant Monoclonal Cullin 3/CUL-3 antibody. Suitable for WB and reacts with Mouse, Rat, Human samples. Cited in 12 publications.
View Alternative Names
KIAA0617, CUL3, Cullin-3, CUL-3
- WB
Unknown
Western blot - Anti-Cullin 3/CUL-3 antibody [EPR3195] (AB108407)
All lanes:
Western blot - Anti-Cullin 3/CUL-3 antibody [EPR3195] (ab108407) at 1/5000 dilution
Lane 1:
HeLa cell lysate at 10 µg
Lane 2:
SH-SY5Y cell lysate at 10 µg
Lane 3:
PC12 cell lysate at 10 µg
Lane 4:
NIH 3T3 cell lysate at 10 µg
Predicted band size: 89 kDa
false
- WB
CiteAb
Western blot - Anti-Cullin 3/CUL-3 antibody [EPR3195] (AB108407)
Cullin 3/CUL-3 western blot using anti-Cullin 3/CUL-3 antibody [EPR3195] ab108407. Publication image and figure legend from Cristini, A., Park, J. H., et al., 2016, Nucleic Acids Res, PubMed 26578593.
ab108407 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab108407 please see the product overview.
The production of DSBs depends on Top1 degradation in CPT-treated quiescent cells. (A–C) Serum-starved WI38 hTERT cells were co-transfected with siRNAs against cullin 3 and cullin 4B or against a control sequence and then treated with DMSO (-CPT) or 25 μM CPT (+CPT) for 1 h. (A and B) Western blot of the indicated proteins. αTubulin : loading control. (C) Number of γH2AX foci per nucleus from one representative experiment (246–348 nuclei were analyzed for each treatment) out of three. ***p < 0.001. (D and E) Serum-starved WI38 hTERT cells were treated with DMSO or MG132 (50 μM) for 1 h before exposure to 0.8 Gy IR. One hour post-irradiation, cells were co-stained for γH2AX (green) and 53BP1 (red). (D) Representative pictures. (E) Number of γH2AX foci per nucleus from one representative experiment (162–180 nuclei were analyzed for each treatment) out of three. Ns : not significant. (F and G) U2OS EV28 cells were treated with DMSO or MG132 (10 μM) for 1 h before the addition of ethanol (untreated) or 300 nM 4-hydroxitamoxifen (4OHT) for 4 h to express AsiSI in the nucleus (42). (F) Representative pictures of cells co-stained for γH2AX (green) and 53BP1 (red). (G) ChIP analysis using an anti-γH2AX antibody (black) or a non-immune antibody (IgG, gray). Enrichment was assessed by QPCR amplification using primers proximal to two AsiSI sites located inside two genes (Gene I : SFRS6, Gene II : CCD47) and primers distal to an AsiSI site (Control). Enrichment was normalized to the maximum recovery for each experiment (means ± SEM, n = 3). Ns : not significant; *p < 0.05. In the microscopic images, nuclear contours, identified by DAPI staining (not shown), are indicated by dashed lines. Bars : 10 μm.
false
Related conjugates and formulations (1)
-
Anti-Cullin 3/CUL-3 antibody [EPR3195] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (12)
Recent publications for all applications. Explore the full list and refine your search
Clinical and experimental medicine 25:243 PubMed40640517
2025
Applications
Unspecified application
Species
Unspecified reactive species
Acta pharmaceutica Sinica. B 14:729-750 PubMed38322326
2024
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of general virology 103: PubMed36301238
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cancer research and treatment 54:525-540 PubMed34237211
2021
Applications
Unspecified application
Species
Unspecified reactive species
Bioengineered 12:2459-2468 PubMed34227919
2021
Applications
Unspecified application
Species
Unspecified reactive species
PloS one 15:e0234708 PubMed32555680
2020
Applications
Unspecified application
Species
Unspecified reactive species
Journal of virology 93: PubMed30814284
2019
Applications
Unspecified application
Species
Unspecified reactive species
Journal of cellular physiology 234:19977-19989 PubMed30945295
2019
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 16:7056-7063 PubMed28901482
2017
Applications
Unspecified application
Species
Unspecified reactive species
Nucleic acids research 44:1161-78 PubMed26578593
2015
Applications
WB
Species
Human
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com